Edwards Lifesciences (EW) Total Current Liabilities (2009 - 2026)

Edwards Lifesciences has reported Total Current Liabilities for 18 years, with the latest figure at $1.5 billion in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 7.35% year-over-year to $1.5 billion in Q2 2026; TTM through Jun 2026 was $1.5 billion, a 7.35% increase from a year earlier, with the FY2025 full-year figure at $1.8 billion, up 20.5% from the prior year.
• Total Current Liabilities was $1.5 billion for Q2 2026 at Edwards Lifesciences, up from $1.4 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $1.9 billion in Q3 2024, with the low at $917.9 million in Q3 2022.
• Average Total Current Liabilities over 5 years is $1.3 billion, with a median of $1.2 billion recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 56.92% in 2024, then dropped 18.32% in 2025.
• Over 5 years, Total Current Liabilities stood at $1.0 billion in 2022, then climbed by 16.92% to $1.2 billion in 2023, then advanced by 25.92% to $1.5 billion in 2024, then gained by 20.5% to $1.8 billion in 2025, then declined by 16.86% to $1.5 billion in 2026.
• The last three Total Current Liabilities figures came in at $1.5 billion (Q2 2026), $1.4 billion (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.